Core One Labs Inc (OTCMKTS: CLABD) has disclosed important information about the significant steps made by its wholly-owned subsidiary, Akome Biotech Ltd. The company speaks about the two major moves by the subsidiary, which happen to be the development of a new working formulation and the filing of another provisional patent application.
Akome admits it is aware of the significant section of people struggling with the deadly Parkinson’s disease and wants to be at the frontline in offering working solutions. This condition is characterized by progressive neurodegeneration that destroys the nerve cells of the affected persons severely.
The substantia nigra happens to be one of the riskiest sections of the brain, which, when affected, plunges the victim into a terrible state of suffering. Experts claim that substantia nigra is the particular section of the brain that controls movement. It is easy to imagine the havoc when such an area is destroyed, and that is why Akome needs to move fast with the development of its AKO004 psychedelic drug formulation.
The development of the AKO004 psychedelic drug formulation is such that it consists of several elements. Those elements include N-dimethyltryptamine (DMT), psychedelic compound N, and a unique naturally occurring plant bioactive. It is essential to mention that Akome Biotech Ltd made its fling with the United States Patent and Trademark Office (USPTO). The filing is said to have been under application number 63147338.
The condition known as neurodegeneration occurs when the brain’s nerve cells or those in the peripheral nervous system fail in their performance and eventually die off. Reports show that almost 10 million people globally are struggling with the condition. Statistics in the U.S. place the figure at 930,000. Other reports show the diagnosis of about 60,000 each year.
The CEO of the Company, Joel Shacker, opines, “Cellular reprogramming has been very progressive over the last decade. Akome’s AKO0004 drug formulation presents strong indication as a viable candidate for the treatment of Parkinson’s disease.”